Your browser doesn't support javascript.
loading
Novel approach treatment of scleroderma lung disease with anti-LFA3 therapy
White, Barbara; Choi, Jung; Wigley, Fredrick M; Wise, Robert A.
Affiliation
  • White, Barbara; University of Maryland. US
  • Choi, Jung; University of Maryland. US
  • Wigley, Fredrick M; University of Maryland. US
  • Wise, Robert A; University of Maryland. US
Rev. chil. reumatol ; 18(3): 85-86, 2002. tab
Article in En | LILACS | ID: lil-340236
Responsible library: CL1.1
ABSTRACT
This pilot trial shows the feasibility of depleting T cells from scleroderma patients, including both the blood and lungs, Alefacept was well tolerated, and T cell depletion was associated with stability in lÅuÅng funtion over the period of the protocol. The data suggest that, at least in part, T cells may drive the non-specific inflammatory response in the lungs of these patients
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Index: LILACS Main subject: Pulmonary Fibrosis / Scleroderma, Localized / T-Lymphocytes Limits: Adult / Female / Humans / Male Language: En Journal: Rev. chil. reumatol / Revista chilena de reumatologia Journal subject: REUMATOLOGIA Year: 2002 Type: Article
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Index: LILACS Main subject: Pulmonary Fibrosis / Scleroderma, Localized / T-Lymphocytes Limits: Adult / Female / Humans / Male Language: En Journal: Rev. chil. reumatol / Revista chilena de reumatologia Journal subject: REUMATOLOGIA Year: 2002 Type: Article